Potential of [11C]TMSX for the evaluation of adenosine A2A receptors in the skeletal muscle by positron emission tomography

Nucl Med Biol. 2004 Oct;31(7):949-56. doi: 10.1016/j.nucmedbio.2004.06.003.

Abstract

We examined the potential of [7-methyl-11C]-(E)-8-(3,4,5-trimethoxystyryl)-1,3,7-trimethylxanthine ([11C]TMSX) for the assessment of adenosine A2A receptors in muscle. In rodents, specific binding of [11C]TMSX was observed in muscle and heart by blockade with A2A-selective CSC and non-selective theophylline, but not with A1-selective DPCPX. Swimming exercise fluctuated radioligand-receptor binding in these tissues. In a PET study of two subjects, theophylline-infusion slightly deceased the distribution volume of [11C]TMSX in the heart (20% reduction) and muscle (10% reduction), which suggested the specific binding.

Publication types

  • Comparative Study
  • Evaluation Study
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Animals
  • Feasibility Studies
  • Humans
  • Male
  • Metabolic Clearance Rate
  • Mice
  • Muscle, Skeletal / diagnostic imaging*
  • Muscle, Skeletal / metabolism*
  • Organ Specificity
  • Positron-Emission Tomography / methods*
  • Radiopharmaceuticals / chemical synthesis
  • Radiopharmaceuticals / pharmacokinetics
  • Rats
  • Receptor, Adenosine A2A / metabolism*
  • Swimming / physiology*
  • Tissue Distribution
  • Xanthines / pharmacokinetics*

Substances

  • KF18446
  • Radiopharmaceuticals
  • Receptor, Adenosine A2A
  • Xanthines